The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.
The agency said the gene therapy should remain on the market while it assesses the situation and does not impact their evaluation of data from the human clinical trials.
The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?
Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.
A 27-year-old man has had right arm numbness for about 2 weeks. What’s in your differential?
For years, study participants had been suffering with migraine symptoms and had failed at least three to five therapies before enrolling in the trial.
Although Alzheimer disease is not infectious by any common definition of the term, research over the past 20 years has confirmed long-standing speculation that the molecular mechanism driving neurodegeneration is fundamentally the same in Alzheimer disease and the prototypical infectious proteopathy—prion disease.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.
A new treatment for NMOSD has been found to reduce relapse, decrease re-hospitalizations, and hinder the need to treat acute attacks with corticosteroids and plasma exchange.
The genomic revolution has led to increasing opportunities to address complex neurodevelopmental conditions, taking a genetics-first approach.
Six months after delivering a healthy baby girl, a physician experiences intermittent blurred vision and tingling in her left leg. Her diagnosis might surprise you.
The latest advances in diagnosis and treatment are discussed in meeting presentations and recent studies and reviews.
MAST study results, remote electrical neuromodulation for acute treatment, and noninvasive vagus nerve stimulation are featured topics.
Because opioids have been shown to increase disability and reduce quality of life in patients with migraine, the search is on for effective alternative treatments.